Medical Device Single-Use Device Reprocessing: Circular Economy, Carbon Footprint Reduction, and the Business Case for Sustainable MedTech in 2026

What This Article Covers

In 2025, hospitals and surgical centers saved $495.5 million and reduced carbon dioxide emissions by more than 125 million pounds (56.7 million kg) by using reprocessed "single-use" medical devices instead of newly manufactured ones, according to the Association of Medical Device Reprocessors (AMDR) annual survey. A record 11,458 healthcare facilities across 18 countries participated. The industry sold more than 39.3 million reprocessed devices back into the healthcare system — an 8.26% increase over 2024 and nearly 24% growth over five years.

This article covers the environmental, economic, and regulatory dimensions of single-use device (SUD) reprocessing as a circular economy strategy in healthcare. It examines peer-reviewed lifecycle assessment data showing that reprocessed devices reduce greenhouse gas emissions by 23–60% compared to original devices, the regulatory frameworks governing reprocessing in the US and EU, the commercial dynamics of the reprocessing industry, and the practical considerations for hospitals and device manufacturers engaging with the circular economy.

What This Article Does NOT Cover

This article focuses on the sustainability and circular economy dimensions of SUD reprocessing. It does not cover general medical device waste management, pharmaceutical waste disposal, or hospital energy efficiency programs. For the regulatory framework governing original device manufacturer obligations around servicing and remanufacturing, see the FDA Servicing vs Remanufacturing Decision Tree Guide. For reusable device reprocessing (cleaning, disinfection, sterilization of instruments designed for reuse), see the Reprocessing Instructions IFU Guide. For sterilization methods, see the Ethylene Oxide Sterilization Guide and the Hydrogen Peroxide Sterilization Guide.

The Scale of Medical Device Waste

Environmental Impact of the Linear Model

Healthcare's carbon footprint is substantial. Research published in Health Affairs found that 80% of healthcare's greenhouse gas emissions originate from the supply chain — the production, transportation, use, and disposal of medical supplies and equipment. Medical devices account for approximately 6–10% of national health systems' carbon footprints, according to a 2025 study published in BMJ Open.

The shift toward single-use devices over the past two decades has exacerbated the waste problem. Over 30 million tons of plastics are produced annually for medical applications, much of it designed for one-time use. A single operating room can generate hundreds of pounds of waste per surgical procedure.

The Carbon Footprint of Surgery

Research published in The Lancet Planetary Health (MacNeill et al., 2017) analyzed the carbon footprint of operating theatres across three health systems and found that surgical suites are among the most resource-intensive areas of a hospital, with significant contributions from anesthesia gases, energy consumption, and single-use consumables.

The linear "take-make-dispose" model that dominates medical device manufacturing and use creates environmental impact across four lifecycle stages: raw material extraction and processing, manufacturing and sterilization, transportation through global supply chains, and end-of-life disposal in landfills or incinerators.

The Reprocessing Solution: Data and Evidence

2025 Industry Performance

The AMDR 2025 annual survey provides the most comprehensive industry-wide data on SUD reprocessing:

Cardinal Health's Sustainable Technologies business, a leading U.S. reprocessor, collected 21.6 million single-use devices and avoided 1,900 metric tons of CO2e emissions in fiscal year 2025 alone.

Peer-Reviewed Lifecycle Assessment Data

Multiple peer-reviewed lifecycle assessments (LCAs) have quantified the environmental advantage of reprocessed devices over original devices:

A 2021 study published in Sustainability found that reprocessing reduces environmental impact in 13 of 16 LCA categories, cutting climate-changing and ozone-depleting emissions by more than half compared to using an original device.

Cost Impact

Reprocessed devices typically cost 30–50% less than newly manufactured equivalents. The economic case is straightforward for hospitals:

• Direct cost reduction: Lower per-unit cost for functionally equivalent devices
• Waste disposal savings: Avoided disposal costs for devices that are collected and reprocessed
• Supply chain resilience: Reduced dependency on original device manufacturer supply chains that may face disruptions
• Budget predictability: Fixed reprocessing pricing vs. variable OEM pricing

How Single-Use Device Reprocessing Works

The Reprocessing Process

SUD reprocessing is not casual reuse. It is a regulated, industrial-scale process that involves:

1. Collection: Used devices are collected from healthcare facilities in designated containers
2. Decontamination and cleaning: Soil and contamination are removed through validated cleaning processes
3. Inspection and testing: Each device undergoes visual, functional, and sometimes dimensional inspection
4. Repair and refurbishment: Components are replaced as needed to restore device function
5. Disinfection and/or sterilization: Devices are sterilized using validated methods — often ethylene oxide (EtO), which is the same sterilant used by OEMs
6. Quality release: Devices undergo final quality checks before being returned to healthcare facilities
7. Tracking and traceability: Each reprocessed device is tracked through the entire lifecycle

Cardinal Health's Australian facility, opening in 2026, illustrates the process: compression sleeves undergo cleaning and disinfection to remove soil and contamination (meeting Australian Therapeutic Goods Regulations requirements), followed by 100% functionality and quality testing, high-level disinfection, and return to hospitals.

Devices Commonly Reprocessed

The most commonly reprocessed device categories include:

• Pulse oximeter sensors
• Lateral transfer mats
• Electrophysiology (EP) catheters
• Compression sleeves (intermittent pneumatic compression)
• Harmonic scalpels / ultrasonic shears
• Surgical cables and connectors
• Endoscopic instruments
• Electrosurgical devices
• Arthroscopic shaver blades
• Diagnostic catheters

Regulatory Framework

FDA Regulation of Reprocessed Devices

In the United States, third-party reprocessors of single-use devices are regulated as medical device manufacturers under the Federal Food, Drug, and Cosmetic Act. This means they must:

• Register with the FDA and list their reprocessed devices
• Submit 510(k) premarket notifications demonstrating substantial equivalence to the original device
• Comply with the Quality System Regulation (QSR), now the Quality Management System Regulation (QMSR) since February 2, 2026
• Comply with Medical Device Reporting (MDR) requirements
• Comply with labeling requirements

The FDA's "servicing vs. remanufacturing" framework, clarified in its 2021 guidance, distinguishes between routine servicing (which does not change the device's specifications) and remanufacturing (which does). Third-party reprocessing that restores a single-use device to its original performance specifications is treated as a manufacturing activity, requiring full regulatory compliance.

EU MDR: Remanufacturing of Single-Use Devices

Under the EU Medical Device Regulation (MDR), the remanufacturing of single-use devices is addressed in Article 17. The MDR imposes specific requirements:

• Remanufacturing must be performed in accordance with the MDR requirements applicable to the original device
• The remanufacturer assumes the obligations of the manufacturer
• The remanufactured device must be covered by a conformity assessment procedure
• The remanufacturer must have a quality management system in place
• The remanufacturer must be identified on the labeling as the manufacturer

The MDR framework is more prescriptive than the US approach, requiring explicit regulatory authorization for remanufacturing activities.

EtO Sterilization and Reprocessing

Both OEMs and reprocessors use ethylene oxide sterilization for invasive medical devices. Reprocessors use the same standardized cycle (AAMI/ANSI/ISO 11135) as the original manufacturer to ensure sterility. From an environmental perspective, the EtO used in reprocessing is equivalent to the EtO used in original manufacturing — the same sterilant, the same cycle, the same standard. The net environmental benefit comes from avoiding the production of an entirely new device.

The Circular Economy Framework

From Linear to Circular

The circular economy model — renew, remake, share — stands in contrast to the linear "take-make-dispose" model. For medical devices, circular economy principles include:

• Design for reprocessing: Designing devices with reprocessing in mind — modular construction, replaceable components, durable materials
• Green servitization: OEM-managed programs where the manufacturer retains ownership and responsibility for device lifecycle
• Reprocessing as a service: Third-party reprocessors providing device collection, reprocessing, and return as a managed service
• Material recovery: Extracting valuable materials from devices at end of life

Research published in Science Direct found that 95% of circular medical devices are reusable, demonstrating the viability of circular approaches in the medical device industry.

The NHS "Design for Life" Roadmap

The UK National Health Service has launched a "Design for Life" roadmap aimed at driving circular economy principles in medical device procurement. The program focuses on reducing waste through design standards that enable remanufacturing, repair, and recycling — moving beyond the current model where most single-use devices are landfilled or incinerated after a single use.

Sustainability Reporting and ESG

As CSRD (Corporate Sustainability Reporting Directive) requirements expand in the EU and ESG reporting becomes standard practice globally, medical device companies face increasing pressure to disclose their environmental footprint. The carbon intensity of single-use device portfolios is becoming a material factor in:

• Hospital procurement decisions
• Health system sustainability targets
• Investor ESG assessments
• Regulatory reporting obligations

For manufacturers, this means that a device portfolio designed for circularity — enabling reprocessing, refurbishment, or material recovery — may command a sustainability premium in institutional purchasing decisions.

Market Dynamics and Competitive Landscape

Circularity Index MedTech 2026

The INDEED Innovation Circularity Index MedTech 2026, published in early 2026, ranked the top medical device companies on their circular economy performance. The findings reveal significant variation:

The study found that durable goods manufacturers (imaging systems, surgical equipment, laboratory instruments) have greater circular economy opportunities through refurbishment, remanufacturing, and life extension. Consumables-focused manufacturers face structural constraints limiting circularity primarily to material substitution and end-of-life recycling. The methodology aligns with European Sustainability Reporting Standards (ESRS) and WBCSD Circular Transition Indicators frameworks.

Key Industry Players

The SUD reprocessing market is concentrated among several major players:

• Cardinal Health Sustainable Technologies: Leading U.S. reprocessor, expanding to Australia in 2026
• Stryker Sustainable Solutions: Major reprocessor with published lifecycle assessment data
• Medline ReNewal: Hospital-focused reprocessing program
• NAM (formerly Practice Greenhealth): Advocate for hospital adoption of reprocessing

OEM Responses

Original device manufacturers have responded to the reprocessing industry in several ways:

• Litigation and lobbying: Some OEMs have pursued legal and regulatory strategies to restrict reprocessing, though FDA regulations affirm the legality of third-party reprocessing
• Green servitization models: Some OEMs are developing their own reprocessing or device-as-a-service programs
• Design changes: Some OEMs have modified device designs to make reprocessing more difficult — a practice that has drawn criticism from sustainability advocates
• Competitive sustainability claims: OEMs are increasingly publishing environmental product declarations and lifecycle data for their devices

Practical Considerations for Hospitals

Starting a Reprocessing Program

Hospitals considering SUD reprocessing should:

1. Audit device spend: Identify which single-use devices currently being discarded are candidates for reprocessing
2. Select a reprocessing partner: Evaluate third-party reprocessors based on FDA compliance, device range, turnaround time, and pricing
3. Establish collection logistics: Set up collection containers and workflows in operating rooms and procedure areas
4. Train staff: Educate clinical and environmental services staff on which devices to collect and how to prepare them
5. Track metrics: Monitor cost savings, waste diversion, and environmental impact to demonstrate ROI and support sustainability reporting

Addressing Safety Concerns

The most common objection to SUD reprocessing is safety. The evidence supports reprocessing as safe when performed by regulated, FDA-compliant reprocessors:

• Reprocessors must demonstrate substantial equivalence to the original device through the 510(k) process
• Each device undergoes individual functional testing before release
• Infection rates associated with reprocessed devices have not been shown to differ from original devices in published studies
• The reprocessing process uses the same sterilization standards (AAMI/ANSI/ISO 11135 for EtO) as OEM manufacturing

Key Takeaways

1. SUD reprocessing saved hospitals $495.5 million and avoided 125+ million pounds of CO2 emissions in 2025, with 11,458 healthcare facilities across 18 countries participating — the circular economy in healthcare is no longer theoretical.

2. Peer-reviewed lifecycle assessments consistently show that reprocessed devices reduce greenhouse gas emissions by 23–60% compared to newly manufactured equivalents, with reductions in 13 of 16 environmental impact categories.

3. Third-party reprocessors are regulated as device manufacturers by the FDA (now under QMSR) and must meet the same quality system requirements as OEMs, including 510(k) clearance for their reprocessed devices.

4. The reprocessing industry grew 8.26% in 2025 and nearly 24% over five years, driven by hospital cost pressures, sustainability mandates, and supply chain resilience goals.

5. For device manufacturers, the circular economy is becoming a competitive factor — hospitals increasingly consider device reprocessability in procurement, ESG reporting requirements reward circular design, and OEMs that ignore sustainability risk losing market share to reprocessing-enabled alternatives.